WeChat Mini Program
Old Version Features
VIPCreated with Sketch.

CML-114: Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib

Jorge Cortes,Elza Lomaia,Anna Turkina,Beatriz Moiraghi,Maria Undurraga Sutton,Carolina Pavlovsky,Christine Rojas,Charles Chuah,Christopher Arthur,Jane Apperley,Dong-Wook Kim,Andreas Hochhaus,Philippe Rousselot,Gianantonio Rosti,Michael Mauro,Jeffrey Lipton,Daniel Naranjo,Guohui Liu,Shouryadeep Srivastava,Michael Deininger

Clinical Lymphoma Myeloma & Leukemia（2020）

Cited 0|Views1
Key words
acute lymphoblastic leukemia,chronic myeloid leukemia,CML,dose-ranging,OPTIC,ponatinib,tyrosine kinase inhibitor,T315I
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined